Tumor News and Research

RSS

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

28 Aug 2009

FDA provides marketing clearance for the spinal implant developed by Sanford Health

Sanford Health, a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device.

28 Aug 2009

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

TomoTherapy Incorporated announced today that there will be more than 40 presentations at the 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy that explore use of the TomoTherapy treatment system. The TomoTherapy system -- a versatile, CT scanner-based device that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting -- is helping cancer centers advance patient care around the world.

28 Aug 2009

Novel methodology developed to extract microRNAs from cancer tissues

Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.

28 Aug 2009

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.

28 Aug 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

Study suspects involvement of PPAR-γ in gastric carcinogenesis

Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.

27 Aug 2009

Studies suggest that venous ischemia causes greater injury than arterial ischemia

The research team led by Professor Guzman-de la Garza of the Autonomous University of Nuevo Leon, Mexico, used a rodent model of intestinal I/R to study the different inflammatory mediators that are associated with venous, arterial or total vascular occlusion.

27 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

Kansas City Cancer Center uses radiation therapy for cancer treatments

Kansas City Cancer Center (KCCC), an affiliate of US Oncology, Inc. which supports the nation's foremost cancer treatment and research network, has treated its first patient with the new TomoTherapy(R) radiation therapy technology at its new KCCC-Shawnee Mission office.

27 Aug 2009

Fight against brain tumor will result in greater awareness and positive outcomes

With this morning's passing of Massachusetts Senator Ted Kennedy from a brain tumor, Wilmington's Christopher Grundner says he feels that it could lead to quicker diagnoses for others affected by the disease and more support for the cause.

27 Aug 2009

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

It is expected that more than 22,000 Americans will be diagnosed with a malignant brain tumor in 2009. Senator Ted Kennedy's death from a brain cancer draws attention to a rare, but often fatal type disease. While the risk of developing brain cancer is relatively low, it is important to heed the warning signs and receive an accurate diagnosis.

27 Aug 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Despite recent advances in diagnosis and treatment, the prognosis of patients with biliary tract cancer is still poor. Elucidating the biological characteristics of these carcinomas has become necessary to improve the prognosis of patients and to devise better treatment strategies. A recent study report that invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in the progression of biliary tract cancer.

26 Aug 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

The American Brain Tumor Association to pursue increased funding of brain tumor research in Senator Kennedy's memory

The following is a statement by Elizabeth Wilson, Executive Director, American Brain Tumor Association on the death of U.S. Senator Edward M. Kennedy: "Senator Kennedy's brain tumor diagnosis just over a year ago brought international attention to this dreadful and devastating disease. He will be remembered as a tireless health care advocate who displayed courage and strength in his final battle against an unrelenting illness.

26 Aug 2009

First Edition: August 26, 2009 - Kennedy dies

Today's headlines focus on the overnight death of Senator Edward Kennedy and his career as one of Washington's most influential lawmakers.

26 Aug 2009

Report suggests that exposure to cellphone radiation causes brain tumors

“Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone,” was released today by a collaborative of international EMF activists. Groups affiliated with the report include Powerwatch and the Radiation Research Trust in the U.K., and in the U.S., EMR Policy Institute, ElectromagenticHealth.org and The Peoples Initiative Foundation. Download the report.

26 Aug 2009

Tumor News and Research

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

FDA provides marketing clearance for the spinal implant developed by Sanford Health

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

Novel methodology developed to extract microRNAs from cancer tissues

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Study suspects involvement of PPAR-γ in gastric carcinogenesis

Studies suggest that venous ischemia causes greater injury than arterial ischemia

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

Kansas City Cancer Center uses radiation therapy for cancer treatments

Fight against brain tumor will result in greater awareness and positive outcomes

More than 22,000 Americans expected to be diagnosed with a malignant brain tumor in 2009

Invasive front dominant expression of LNγ2 and LNβ3 and active MMP7 play a key role in biliary tract cancer

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The American Brain Tumor Association to pursue increased funding of brain tumor research in Senator Kennedy's memory

First Edition: August 26, 2009 - Kennedy dies

Report suggests that exposure to cellphone radiation causes brain tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News